EA201991288A1 - Фармацевтические композиции на основе дабигатрана - Google Patents

Фармацевтические композиции на основе дабигатрана

Info

Publication number
EA201991288A1
EA201991288A1 EA201991288A EA201991288A EA201991288A1 EA 201991288 A1 EA201991288 A1 EA 201991288A1 EA 201991288 A EA201991288 A EA 201991288A EA 201991288 A EA201991288 A EA 201991288A EA 201991288 A1 EA201991288 A1 EA 201991288A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dabigatran
pharmaceutical compositions
compositions based
pharmaceutically acceptable
dabigatran etexilate
Prior art date
Application number
EA201991288A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991288A1 publication Critical patent/EA201991288A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции в форме заключенных в капсулу мини-таблеток, содержащей свободное основание дабигатрана этексилата или фармацевтически приемлемые соли дабигатрана этексилата и по меньшей мере одно фармацевтически приемлемое вспомогательное вещество.
EA201991288A 2016-12-07 2017-12-06 Фармацевтические композиции на основе дабигатрана EA201991288A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2016/17984A TR201617984A2 (tr) 2016-12-07 2016-12-07 Dabi̇gatranin farmasöti̇k kompozi̇syonlari
PCT/EP2017/081639 WO2018104370A1 (en) 2016-12-07 2017-12-06 Pharmaceutical compositions of dabigatran

Publications (1)

Publication Number Publication Date
EA201991288A1 true EA201991288A1 (ru) 2019-10-31

Family

ID=60582497

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991288A EA201991288A1 (ru) 2016-12-07 2017-12-06 Фармацевтические композиции на основе дабигатрана

Country Status (4)

Country Link
EP (2) EP3551172A1 (ru)
EA (1) EA201991288A1 (ru)
TR (2) TR201617984A2 (ru)
WO (1) WO2018104370A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113933400B (zh) * 2020-06-29 2024-01-12 石药集团恩必普药业有限公司 一种达比加群酯原料药或制剂中基因毒性杂质的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DK1485094T4 (da) 2002-03-07 2020-06-22 Boehringer Ingelheim Int Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte
DE102005020002A1 (de) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
WO2012077136A2 (en) 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
IN2013CH05441A (ru) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd
IN2014MU01042A (ru) * 2014-03-26 2015-10-02 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
EP3551172A1 (en) 2019-10-16
TR201617984A2 (tr) 2018-06-21
TR201619828A2 (en) 2018-06-21
EP3332770A1 (en) 2018-06-13
WO2018104370A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
EA201891489A1 (ru) Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
CL2015002897A1 (es) Inhibidores de bace1
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA201791009A1 (ru) Композиции, содержащие циклоспорин
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
EA201890944A1 (ru) Фармацевтические композиции нилотиниба гидрохлорида
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
MX2017012022A (es) Compuestos organicos.
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
EA201991288A1 (ru) Фармацевтические композиции на основе дабигатрана
WO2019004980A3 (en) SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA201890477A1 (ru) Инкапсулированная композиция финголимода
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
TR201722323A2 (tr) Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722630A2 (ru)